Slide 1: Revolutionary Treatments for Cancer – Annual General Meeting
For personal use only Patrys Ltd (ASX: PAB) www.patrys.com Revolutionary Treatments for Cancer Annual General Meeting 29 October 2010 Dan Devine Chief Executive Officer 1
Slide 2: Company Overview
Company Overview For personal use only Transformation to a clinical stage company Organisation Headquarters (Melbourne), R&D (Germany), Manufacturing (U.S.) Objective Developing revolutionary treatments for cancer PAT-SM6: commenced first-in-human clinical trial in melanoma Clinical Products
Slide 3: Financial Overview
Financial Overview For personal use only Listing ASX (Jul 2007): PAB Shares on Issue 192,275,910 Market Cap $17.7 million (Oct 2010) $7 million (June 2010) Cash $15 million facility Type 2007 2010 Retail 29% 38% Share Registry Institution 31% 14% Founder/Management 40% 48% 2008: 50,000 A
Slide 4: Milestones Achieved
Milestones Achieved For personal use only Acquisition of clinical product PAT-SC1 Oct 2009 Strengthening of key value CSL collaboration signed Jan 2010 drivers First CSL milestone reached earning payment May 2010 Maturity and depth of 3 new lead products from internal library June 2010 pipelin
Slide 5: Natural Human Antibodies to Cancer
Natural Human Antibodies to Cancer For personal use only Potency: Humans generate cancer cells regularly, but the human immune system, including antibodies, effectively prevents diagnosable cancer in >99.8% of general population* Safety: Human antibodies naturally ignore healthy tissue, thereby
Slide 6: Internal Pipeline
Internal Pipeline For personal use only Multiple and Diverse Products = Balanced “Portfolio” of Assets 6
Slide 7: PAT-SC1 Lead Candidate (Gastric Cancer)
PAT-SC1 Lead Candidate (Gastric Cancer) For personal use only Human Survival benefit for treated Trial patients vs. historic control Patient Survival Results Well tolerated 1.0 Stage/ Converting to PER.C6® Treated patients Next manufacturing platform 0.8 Steps Phase II human trial (2011)* ~9
Slide 8: PAT-SM6 Lead Candidate (Multiple Cancers)
PAT-SM6 Lead Candidate (Multiple Cancers) For personal use only Broad Applies to multiple cancers including melanoma, Applications breast, colon and pancreatic Safe profile in laboratory and in vivo experiments; Safety no binding to healthy tissues Melanoma clinical trial approved Stage Firs
Slide 9: PAT-LM1 Lead Candidate (Multiple Cancers)
PAT-LM1 Lead Candidate (Multiple Cancers) For personal use only Broad Applies to multiple cancers including colon, Lung Cancer Xenograft Tumour Model Applications pancreatic, lung, breast, ovary and prostate Safe profile in preclinical safety studies no Safety binding to healthy tissues Stage
Slide 10: CSL Collaboration/Partnering
CSL Collaboration/Partnering Commercial relationship with Australia’s largest biopharmaceutical For personal use only company, CSL Limited Covers up to 4 early stage assets (not including most mature products PAT-SM6, PAT-SC1, PAT-LM1 and PAT-PA1) Benefit from the advancement of several produc
Slide 11: Competitive Position - I
Competitive Position - I Product Advantages For personal use only Characteristic Patrys Products Potential Benefits Kill cancer cells Safety Specificity No detectable impact on healthy tissues Potency Products on market attack both Dosing Patrys antibodies apply to many cancers Clini
Slide 12: Competitive Position – II
Competitive Position – II Novel Targets For personal use only Antibody therapy market is focused on “optimised” Disease Drug Competing antibodies to targets with no or Target (Sales US$B) Products expiring patent protection CD20 Rituxan ($8.7) 10 EGFR Erbitux ($.94) 12 Substantial industry deman
Slide 13: Competitive Position – III
Competitive Position – III Patent Portfolio For personal use only Priority Family Dates Broad protection of molecules, disease PAT-SC1 1998 targets, mechanism of action, uses and PAT-PA1 2001 manufacturing PAT-CM1 2002 PAT-LM1 2003, 2009 Unique and differentiating position in PAT-CM2 2002 increa
Slide 14: Expected News Flow CY2011
Expected News Flow CY2011 For personal use only PAT-SM6 human clinical trial data (1H) Results from collaboration with CSL Limited (1H) New products to pipeline from internal R&D (1H/2H) Patents filed and issued for lead products (1H/2H) Initiate larger PAT-SM6 trial (late 1H/early 2H) S
Slide 15: Increasing Activity in Natural Human Antibody Space
Increasing Activity in Natural Human Antibody Space For personal use only Market Depth and breadth of Disease pipeline, IP and technologies Company Cap Product Stage Indication US$B provides Patrys with a strong first mover position Nascent Pritumumab Brain Private Phase II Biologics IgG1 kappa ca
Slide 16: Antibody Market: Well Established
Antibody Market: Well Established For personal use only Total Antibody Therapy Sales US$B Antibody Product/Company Values US$M 2010 $60 $1,000 $867 $900 2009 $42 $800 M&A Company Average US$ million $700 Values $612 2008 $33 $600 $500 $340 2007 $26 $400 $300 Product/License Values 2006 $16.5 $200 $1
Slide 17: Summary
Summary For personal use only Strong competitive position in growing biotechnology segment Targeting large unmet medical needs Diverse & multiple opportunities - “portfolio” investment Moving from preclinical to clinical status – value generation opportunity Upside from ability to form str
Slide 18: For Further Information
For Further Information For personal use only Contact Details Dan Devine, Chief Executive Officer Marie Roskrow, Chief Medical Officer & President Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com 18